Real ResearchS.A.
Research and experimental development in natural sciences and engineering
Overview
REAL Research helps scientists move from 2D to 3D cell culture. It offers LifeGel, a ready-to-use hydrogel for 3D cell culture. The company focuses on more physiologically relevant models for life science.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
3D cell culture in drug discovery
3D cell culture provide an excellent alternative to currently routinely used methods during traditional preclinical procedures.
Real, Three Dimensional Research
Discovery of the 3D cell culture gave us new capabilities in many fields of science, especially drugs discovery.
Interview with Marcin Krzykawski
Recently, Marcin Krzykawski gave an interesting and extensive interview during...
2020 AMBASSADOR OF INNOVATION
Our projects and innovative solutions have been appreciated by the...
M. Krzykawski on EACR/AACR
Marcin Krzykawski (CEO Real Research) was participating in EACR/AACR (in partnership...
September 2020
Let’s meet at “3D ONCOLOGY&TISSUE MODELS SUMMIT” 30 Sept-01 Oct...
Bank accounts
Registered as a VAT taxpayer on 2018-06-02. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
33 public aid cases recorded, with a total value of $2,522,638.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Apr 9, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $14,561$14,561 | Fundacja Klaster Lifescience Kraków | |
| Jan 26, 2024 | Aid for research and development projects: industrial research | $896.2K$896,248 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Jan 26, 2024 | Aid for research and development projects: experimental development | $154.3K$154,328 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
4 projects recorded: 3 from FE lists ($2,107,495) and 1 Commission grant (FTS) ($202,283).
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-01-01 | Opracowanie innowacyjnego, gotowego do użycia modelu opartego na hodowlach 3D do przedklinicznych badań nowych terapii celowanych i immunoterapii raka płuca i jajnika. | $1.1M$1,056,716 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2022-10-01 | 101079510 - Canvas - enhancing cancer vaccine science for new therapy pathways | $202.3K$202,283 | 1.0.11 - Horizon Europe | |
| 2021-01-01 | OPRACOWANIE I WDROŻENIE NOWATORSKIEJ USŁUGI POLEGAJĄCEJ NA BADANIU WRAŻLIWOŚCI TKANKI NOWOTWOROWEJPOBRANEJ OD PACJENTA NA ZESTAW CHEMIOTERAPEUTYKÓW W CELU DOBRANIA POTENCJALNIE NAJSKUTECZNIEJSZEJ TERAPII | $427.4K$427,446 | Regionalny Program Operacyjny Województwa Małopolskiego na lata 2014-2020 |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
In the case of a multi-member management board, declarations of will, signing documents on behalf of the company and granting powers of attorney require the joint action of two members of the management board, including in every case the Vice-President of the Management Board, provided that the Vice-President of the Management Board has been appointed.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Renata - Krzykawska (34)  | Shareholder of a joint-stock company, 33.79% | |
Marcin Przemysław Krzykawski (42) | Shareholder of a joint-stock company, 34.24% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| MedappS.A. | $3,351,163.61 | medapp.pl | ||
| PolbionicaS.A. | $356,011.70 | polbionica.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-08-07 | Share capital change (518,498.00 PLN → 528,348.00 PLN) | |
| 2024-10-07 | Share capital change (499,884.00 PLN → 518,498.00 PLN) | |
| 2024-07-19 | Entered in the register |
FAQ
Last updated: 2026-07-04